...
uthr-img

United Therapeutics Corporation, Common Stock

UTHR

NSQ

$359.58

-$0.58

(-0.16%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$16.08B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
15.8173
Volume info-icon
This is the total number of shares traded during the most recent trading day.
706.51K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.56
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$208.62 L
$417.81 H
$359.58

About United Therapeutics Corporation, Common Stock

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameUTHRSectorS&P500
1-Week Return-0.62%-2.12%-3%
1-Month Return-1.3%-3.42%-0.73%
3-Month Return1.86%-11.13%2.87%
6-Month Return16.38%-5.74%7.17%
1-Year Return59.45%3.97%25.31%
3-Year Return77.82%1.05%28.38%
5-Year Return297.81%34.37%81.89%
10-Year Return168.7%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue1.45B1.48B1.69B1.94B2.33B[{"date":"2019-12-31","value":62.25,"profit":true},{"date":"2020-12-31","value":63.73,"profit":true},{"date":"2021-12-31","value":72.42,"profit":true},{"date":"2022-12-31","value":83.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue117.60M108.10M122.50M146.70M257.50M[{"date":"2019-12-31","value":45.67,"profit":true},{"date":"2020-12-31","value":41.98,"profit":true},{"date":"2021-12-31","value":47.57,"profit":true},{"date":"2022-12-31","value":56.97,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit1.33B1.38B1.56B1.79B2.07B[{"date":"2019-12-31","value":64.31,"profit":true},{"date":"2020-12-31","value":66.43,"profit":true},{"date":"2021-12-31","value":75.51,"profit":true},{"date":"2022-12-31","value":86.45,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin91.88%92.71%92.73%92.42%88.94%[{"date":"2019-12-31","value":99.08,"profit":true},{"date":"2020-12-31","value":99.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.67,"profit":true},{"date":"2023-12-31","value":95.91,"profit":true}]
Operating Expenses1.52B781.60M1.01B809.90M885.10M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":51.46,"profit":true},{"date":"2021-12-31","value":66.31,"profit":true},{"date":"2022-12-31","value":53.32,"profit":true},{"date":"2023-12-31","value":58.28,"profit":true}]
Operating Income(187.60M)593.60M555.90M979.70M1.18B[{"date":"2019-12-31","value":-15.83,"profit":false},{"date":"2020-12-31","value":50.1,"profit":true},{"date":"2021-12-31","value":46.92,"profit":true},{"date":"2022-12-31","value":82.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense24.90M50.40M36.10M(16.30M)192.80M[{"date":"2019-12-31","value":12.91,"profit":true},{"date":"2020-12-31","value":26.14,"profit":true},{"date":"2021-12-31","value":18.72,"profit":true},{"date":"2022-12-31","value":-8.45,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(165.00M)638.90M593.90M950.60M1.27B[{"date":"2019-12-31","value":-12.95,"profit":false},{"date":"2020-12-31","value":50.14,"profit":true},{"date":"2021-12-31","value":46.61,"profit":true},{"date":"2022-12-31","value":74.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income Taxes(60.50M)124.10M118.10M223.30M289.50M[{"date":"2019-12-31","value":-20.9,"profit":false},{"date":"2020-12-31","value":42.87,"profit":true},{"date":"2021-12-31","value":40.79,"profit":true},{"date":"2022-12-31","value":77.13,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(104.50M)514.80M475.80M727.30M984.80M[{"date":"2019-12-31","value":-10.61,"profit":false},{"date":"2020-12-31","value":52.27,"profit":true},{"date":"2021-12-31","value":48.31,"profit":true},{"date":"2022-12-31","value":73.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income From Continuous Operations(104.50M)514.80M475.80M727.30M984.80M[{"date":"2019-12-31","value":-10.61,"profit":false},{"date":"2020-12-31","value":52.27,"profit":true},{"date":"2021-12-31","value":48.31,"profit":true},{"date":"2022-12-31","value":73.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(104.50M)514.80M475.80M727.30M984.80M[{"date":"2019-12-31","value":-10.61,"profit":false},{"date":"2020-12-31","value":52.27,"profit":true},{"date":"2021-12-31","value":48.31,"profit":true},{"date":"2022-12-31","value":73.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
EPS (Diluted)11.2811.5810.0315.0219.84[{"date":"2019-12-31","value":56.85,"profit":true},{"date":"2020-12-31","value":58.37,"profit":true},{"date":"2021-12-31","value":50.55,"profit":true},{"date":"2022-12-31","value":75.71,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

UTHR
Cash Ratio 3.81
Current Ratio 4.58
Quick Ratio 4.41

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

UTHR
ROA (LTM) 11.89%
ROE (LTM) 18.81%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

UTHR
Debt Ratio Lower is generally better. Negative is bad. 0.14
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

UTHR
Trailing PE 15.82
Forward PE 12.82
P/S (TTM) 5.83
P/B 2.62
Price/FCF 53
EV/R 4.73
EV/Ebitda 8.38
PEG 0.73

FAQs

What is United Therapeutics Corporation share price today?

United Therapeutics Corporation (UTHR) share price today is $359.58

Can Indians buy United Therapeutics Corporation shares?

Yes, Indians can buy shares of United Therapeutics Corporation (UTHR) on Vested. To buy United Therapeutics Corporation from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in UTHR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of United Therapeutics Corporation be purchased?

Yes, you can purchase fractional shares of United Therapeutics Corporation (UTHR) via the Vested app. You can start investing in United Therapeutics Corporation (UTHR) with a minimum investment of $1.

How to invest in United Therapeutics Corporation shares from India?

You can invest in shares of United Therapeutics Corporation (UTHR) via Vested in three simple steps:

  • Click on Sign Up or Invest in UTHR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in United Therapeutics Corporation shares
What is United Therapeutics Corporation 52-week high and low stock price?

The 52-week high price of United Therapeutics Corporation (UTHR) is $417.81. The 52-week low price of United Therapeutics Corporation (UTHR) is $208.62.

What is United Therapeutics Corporation price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of United Therapeutics Corporation (UTHR) is 15.8173

What is United Therapeutics Corporation price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of United Therapeutics Corporation (UTHR) is 2.62

What is United Therapeutics Corporation dividend yield?

The dividend yield of United Therapeutics Corporation (UTHR) is 0.00%

What is the Market Cap of United Therapeutics Corporation?

The market capitalization of United Therapeutics Corporation (UTHR) is $16.08B

What is United Therapeutics Corporation’s stock symbol?

The stock symbol (or ticker) of United Therapeutics Corporation is UTHR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top